Brokers Issue Forecasts for XENE Q1 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities researchers at HC Wainwright issued their Q1 2027 EPS estimates for Xenon Pharmaceuticals in a report issued on Friday, August 7th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of ($1.21) for the quarter. HC Wainwright has a “Buy” rating and a $74.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($4.91) per share.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the firm earned ($1.07) earnings per share.

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC lowered their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Royal Bank Of Canada lowered their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a report on Friday. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $77.13.

Xenon Pharmaceuticals Stock Down 1.6%

Shares of Xenon Pharmaceuticals stock opened at $63.22 on Monday. Xenon Pharmaceuticals has a fifty-two week low of $35.10 and a fifty-two week high of $72.66. The business’s fifty day moving average is $60.67 and its two-hundred day moving average is $54.62. The firm has a market cap of $6.11 billion, a PE ratio of -13.34 and a beta of 0.62.

Insiders Place Their Bets

In related news, Director Gary Patou sold 1,322 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director directly owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director directly owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.91% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Xenon Pharmaceuticals during the second quarter valued at approximately $454,057,000. Avoro Capital Advisors LLC increased its position in shares of Xenon Pharmaceuticals by 0.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock worth $243,124,000 after acquiring an additional 24,444 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Xenon Pharmaceuticals by 2.3% in the first quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock worth $242,858,000 after acquiring an additional 91,948 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after acquiring an additional 1,435,096 shares during the period. Finally, Capital International Investors raised its stake in shares of Xenon Pharmaceuticals by 7.3% in the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after acquiring an additional 233,466 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals News Roundup

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $74 price target, above the stock’s recent trading level near $63. The firm raised its EPS forecasts for 2026 through 2030, including a narrower expected loss of $4.48 per share in fiscal 2026, $4.88 in 2027, $3.89 in 2028, $2.23 in 2029 and $0.18 in 2030. The revisions suggest the analyst expects Xenon’s losses to narrow faster than previously projected. HC Wainwright estimates for Xenon Pharmaceuticals
• Neutral Sentiment: Reported short-interest data showed zero shares sold short as of August 11, compared with zero shares in the prior reporting period, producing a zero-day days-to-cover ratio. Because the report also displays an invalid “NaN” percentage change, it offers no meaningful indication of changing bearish positioning or potential short-covering support.
• Negative Sentiment: Xenon is still expected to report substantial losses, with consensus fiscal-year EPS of negative $4.92 and HC Wainwright forecasting additional quarterly losses through 2027. As a development-stage biopharmaceutical company, XENE remains dependent on clinical and commercial execution, while the provided updates contain no new drug-development or regulatory catalyst. Equities Analysts Set Expectations for XENE Q1 Earnings

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.